Marking 75 years of advancing cancer research, the Swedish Cancer Society hosted Momentum 2026 – an international conference focused on accelerating Europe's translation of cancer research into patient benefit.
Momentum took place on 14–16 October at Artipelag in Stockholm, Sweden, bringing together participants from across Europe for a three-day, in-person conference.

Momentum demonstrated the value of bringing together people from across the cancer community, including researchers, healthcare professionals, policymakers, patient organisations, industry, investors and funders, each bringing different perspectives and expertise. What struck me most was not only the depth of knowledge in the room, but also the willingness to challenge established ways of working and explore new solutions.
The discussions showed what Europe could achieve through stronger cross-border clinical research, better use of health data and greater investment in cancer research and innovation. By working more closely together, we can accelerate the development of new treatments and help more patients benefit from scientific advances. Throughout the conference, one message remained clear: patients’ needs and perspectives must be at the heart of everything we do.
Europe has enormous expertise and commitment. Now we need to build on these strengths and turn collaboration into real progress for patients. I believe Momentum brought us closer to that goal. Seeing the energy and commitment of participants, panellists, speakers and the Momentum working group makes me both proud and hopeful.
Ultimately, progress must be measured not only by scientific breakthroughs, but by the difference they make in patients’ lives.
Ulrika Årehed Kågström
Secretary General, The Swedish Cancer Society
Birgitta Ohlossn, Member of the Swedish Parliament, Centerpartiet, and former minister shares learnings from her transatlantic patient journey.
Elisabete Weiderpass, Director - International Agency for Research on Cancer (IARC) gives a broad perspective on what is at stake for Europé and why it matters now.
Momentum hall at Artipelag, Stockholm.
Greg Simon, Former Executive Director - White House Cancer Moonshot Task Force shares the major cancer initiatives in the US, the differences from Europe and key learnings.
Momentum gathered more than 200 participants from across the entire cancer ecosystem – researchers, healthcare professionals, policymakers, patient organisations, industry, investors and funders.
Joanna Drake, Deputy Director-General - The European Commission’s Directorate-General for Research and Innovation (DG RTD) shares the major cancer initiatives in Europé, the ambitions and learnings.
The Momentum Working Group with the mission to identify concrete ways to strengthen academic-led multinational clinical trials in Europé. From the left: Robrecht Lembrechts, Kom op Tegen Kanker (Belgium), Marina Reguero Simon – Scientific Foundation of the Spanish Association Against Cancer (Spain), Miranda Wijdenes – KWF Dutch Cancer Society (Netherlands), Annina Graan – Swedish Cancer Society (Sweden), Kim Ramme – Swedish Childhood Cancer Fund (Sweden), Gauthier Bouche – Anti Cancer Fund, (Belgium).
Niklas BlombergExecutive Director - Innovative Health Initiative (IHI).
Panel discussion – bridging research and care. From the left: Karin Hübinette, moderator, Ingrid Glimelius, Professor, Senior Consultant - Uppsala University and Uppsala University Hospital, Michael Baumann, Professor and Director - German cancer research center, President of EACS, Niklas Hedberg, Chief Pharmacist - Swedish Dental and Pharmaceutical Benefits Agency (TLV), Eva Jolly – Former Member of the European Parliament (MEP).
Ulrika Årehed Kågström, Secretary General at the Swedish Cancer Society and Former President of UICC.
Panel discussion: On the EU Agenda. From the left: Karin Hübinette, moderator, Fabio D’Atri, Policy Officer, European Commission DG SANTE, Sara Lowemark, Director International Affairs, Lif, Giacomo Capone, PhD, Scientific Specialist, European Medicines Agency, Wolfgang Fecke, Executive Director, Association of European Cancer Leagues (ECL).
Momentum workshop.
Sweden has the tools to eliminate cervical cancer: HPV vaccines and screening. Professor Joakim Dillner helped drive a national project to achieve this goal. In this film, he explains how collaboration makes it possible.
Researcher Lao Saal had a clear vision for his work and he succeeded in creating a blood test that detects cancer long before a recurrence can be seen on scans or causes symptoms.
Here are some voices from the first day of the meeting.
Here are some voices from the second day of the meeting.
Momentum brought together policymakers, researchers, healthcare leaders, patient representatives, industry, investors and civil society from across Europe to explore how stronger collaboration across sectors and borders could accelerate progress in cancer research and care.
Discussions focused on clinical research, regulation, health data, investment and access to innovation, with a shared ambition to ensure that scientific advances reach patients faster and more equitably.
The conference aimed to identify concrete opportunities for collaboration and action, contributing to more effective, sustainable and equitable cancer care across Europe.

The Swedish Cancer Society is an independent, non-profit organisation working to beat cancer by funding research, spreading knowledge and influencing decision-makers.
We are one of the largest funders of cancer research in Sweden. Our work depends on gifts and donations from individuals and companies. Each year, we contribute 1 billion Swedish kronor to leading cancer research.